{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McCune JS"],"funding":["American Cancer Society","National Cancer Institute","Beckman Research Institute, City of Hope","NCI NIH HHS","National Institute of General Medical Sciences","NIGMS NIH HHS"],"pagination":["322-331"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10622331"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(2)"],"pubmed_abstract":["<h4>Introduction</h4>Medication nonadherence continues to be challenging for allogeneic hematopoietic cell transplant (HCT) recipients. The risk and severity of chronic graft-versus-host disease (GVHD) are associated with low immunosuppressant concentrations (which can be improved with model-informed precision dosing (MIPD)) and with immunosuppressant nonadherence (which can be improved with acceptable interventions).<h4>Methods</h4>With the goals of improving adherence and achieving therapeutic concentrations of immunosuppressants to eliminate GVHD, we characterized the feasibility of using the Medication Event Monitoring (MEMS<sup>®</sup>) Cap in adult HCT recipients.<h4>Results</h4>Of the 27 participants offered the MEMS<sup>®</sup> Cap at the time of hospital discharge, 7 (25.9%) used it, which is below our a priori threshold of 70%. These data suggest the MEMS<sup>®</sup> Cap is not feasible for HCT recipients. The MEMS<sup>®</sup> Cap data were available for a median of 35 days per participant per medication (range: 7-109 days). The average daily adherence per participant ranged from 0 to 100%; four participants had an average daily adherence of over 80%.<h4>Conclusions</h4>MIPD may be supported by MEMS<sup>®</sup> technology to provide the precise time of immunosuppressant self-administration. The MEMS<sup>®</sup> Cap was used by only a small percentage (25.9%) of HCT recipients in this pilot study. In accordance with larger studies using less accurate tools to evaluate adherence, immunosuppressant adherence varied from 0% to 100%. Future studies should establish the feasibility and clinical benefit of combining MIPD with newer technology, specifically the MEMS<sup>®</sup> Button, which can inform the oncology pharmacist of the time of immunosuppressant self-administration."],"journal":["Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners"],"pubmed_title":["Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients."],"pmcid":["PMC10622331"],"funding_grant_id":["R01 GM129863","U01 CA239373","U01CA239373","P30 CA033572","P30CA033572","California Institute of Technology – City of Hop","City of Hope&apos;s Center for Cancer and Aging","RSG-21-181-01-CTPS","R01GM129863"],"pubmed_authors":["Shan H","McCune JS","Armenian SH","Mielcarek M","Gao W","Nakamura R","Mager DE","Kanakry CG"],"additional_accession":[]},"is_claimable":false,"name":"Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients.","description":"<h4>Introduction</h4>Medication nonadherence continues to be challenging for allogeneic hematopoietic cell transplant (HCT) recipients. The risk and severity of chronic graft-versus-host disease (GVHD) are associated with low immunosuppressant concentrations (which can be improved with model-informed precision dosing (MIPD)) and with immunosuppressant nonadherence (which can be improved with acceptable interventions).<h4>Methods</h4>With the goals of improving adherence and achieving therapeutic concentrations of immunosuppressants to eliminate GVHD, we characterized the feasibility of using the Medication Event Monitoring (MEMS<sup>®</sup>) Cap in adult HCT recipients.<h4>Results</h4>Of the 27 participants offered the MEMS<sup>®</sup> Cap at the time of hospital discharge, 7 (25.9%) used it, which is below our a priori threshold of 70%. These data suggest the MEMS<sup>®</sup> Cap is not feasible for HCT recipients. The MEMS<sup>®</sup> Cap data were available for a median of 35 days per participant per medication (range: 7-109 days). The average daily adherence per participant ranged from 0 to 100%; four participants had an average daily adherence of over 80%.<h4>Conclusions</h4>MIPD may be supported by MEMS<sup>®</sup> technology to provide the precise time of immunosuppressant self-administration. The MEMS<sup>®</sup> Cap was used by only a small percentage (25.9%) of HCT recipients in this pilot study. In accordance with larger studies using less accurate tools to evaluate adherence, immunosuppressant adherence varied from 0% to 100%. Future studies should establish the feasibility and clinical benefit of combining MIPD with newer technology, specifically the MEMS<sup>®</sup> Button, which can inform the oncology pharmacist of the time of immunosuppressant self-administration.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-18T12:52:39.432Z","creation":"2025-04-06T22:16:16.415Z"},"accession":"S-EPMC10622331","cross_references":{"pubmed":["37134196"],"doi":["10.1177/10781552231171607"]}}